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Owing to the lack of oral drugs for human African trypanosomiasis, patients have to be hospitalized for
10 to 30 days to facilitate treatment with parenterally administered medicines. The efficacy of a novel
orally administered prodrug, 2,5-bis(4-amidinophenyl)-furan-bis-O-methlylamidoxime (pafuramidine,
DB289), was tested in the vervet monkey (Chlorocebus [Cercopithecus] aethiops) model of sleeping sickness.
Five groups of three animals each were infected intravenously with 104 Trypanosoma brucei rhodesiense
KETRI 2537 cells. On the seventh day postinfection (p.i.) in an early-stage infection, animals in groups
1, 2, and 3 were treated orally with pafuramidine at dose rates of 1, 3, or 10 mg/kg of body weight,
respectively, for five consecutive days. The animals in groups 4 and 5 were treated with 10 mg/kg for 10
consecutive days starting on the 14th day p.i. (group 4) or on the 28th day p.i. (group 5), when these
animals were in the late stage of the disease. In the groups treated in the early stage, 10 mg/kg of
pafuramidine completely cured all three monkeys, whereas lower doses of 3 mg/kg and 1 mg/kg cured only
one of three and zero of three monkeys, respectively. Treatment of late-stage infections resulted in cure
rates of one of three (group 4) and zero of three (group 5) monkeys. These studies demonstrated that
pafuramidine was orally active in monkeys with early-stage T. brucei rhodesiense infections at dose rates
above 3 mg/kg for 5 days. It was also evident that the drug attained only minimal efficacy against late-stage
infections, indicating the limited ability of the molecule to cross the blood-brain barrier. This study has
shown that oral diamidines have potential for the treatment of early-stage sleeping sickness.
Human African trypanosomiasis (HAT) (sleeping sickness)
is caused by the flagellated protozoan parasites Trypanosoma
brucei gambiense and T. brucei rhodesiense and is inevitably
fatal when untreated. The disease is endemic to sub-Saharan
Africa, where an estimated 50 million people in more than 20
countries are considered to be at risk (23). WHO statistics
show that from 1998 to 2004, the number of HAT cases de-
clined from 37,991 to 17,616 (30), and the estimated preva-
lence declined in the same period, from 300,000 to 500,000
cases to 50,000 to 70, 000, even though the number of people
covered by active screening almost doubled in the same period
(30). These declining trends are indicators that the partner-
ships between individual African governments and the WHO
are having a positive impact on the control of HAT. However,
these gains could easily be lost through political instability
and/or the outbreak of wars, which inevitably lead to a break-
down in surveillance activities (10). At present, HAT remains
a major health problem in certain foci in the Democratic Re-
public of Congo, Angola, and Southern Sudan (10, 30). Since
the trypanosomes’ remarkable ability to vary their major sur-
face antigen makes successful vaccine development unlikely in
the near future (26), the only recourse available is to intensify
research and the development of new drugs.
Current drugs that are used to treat HAT include pentam-
idine, suramin, melarsoprol, and eflornithine (5). These are far
from ideal, since they elicit substantial toxic effects and/or
require parenteral application, which makes them difficult to
administer in the rural African settings where the disease typ-
ically occurs. Furthermore, melarsoprol, the only drug avail-
able that is effective against the late stages of both T. brucei
gambiense and T. brucei rhodesiense disease, has shown inci-
dences of treatment failure of 25% in epidemic areas of
northern Uganda and northern Angola (4, 7, 8). Both melar-
soprol and eflornithine require long periods of hospitalization
and monitoring owing to the complicated treatment schedules
needed (1). In addition, melarsoprol may cause reactive en-
cephalopathy; this occurs in 5 to 10% of treated patients and
has a fatality rate of 50% (5). The provision of an oral drug
of low toxicity for sleeping sickness would allow an effective
administration of the required doses with minimal supervision
from medical personnel. This is an important consideration,
since enough qualified people are rarely available in those
parts of Africa where the disease is endemic.
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A recently synthesized novel prodrug, 2,5-bis(4-amidinophe-
nyl)-furan-bis-O-methlylamidoxime (pafuramidine, DB289)
exhibited excellent oral activity and reduced acute toxicity in
acute and chronic mouse models of trypanosomiasis (3, 12, 27).
The enhanced oral activity of DB289 is attributed to an im-
proved oral absorption of the prodrug in which the cationic
functionalities are masked and to its conversion to the active
compound 2,5-bis(4-amidinophenyl)furan (furamidine; DB75)
in the liver. DB75 strongly binds to the minor groove of DNA
at AT-rich sites and weakly binds by intercalation at the GC
sites of DNA (25). Consequently, its subsequent mode of ac-
tion involves interference with the normal function of the
pathogen’s DNA-dependent enzymes, perhaps topoisomerase
II (2). In spite of pafuramidine being an analogue of pentam-
idine, it appears to possess two properties that would overcome
the two disadvantages of pentamidine, namely, parenteral ad-
ministration and lack of efficacy against central nervous system
(CNS) infection.
Recently, following prolonged administration with the drug
in a clinical trial for AIDS, abnormal liver enzyme values were
found in several volunteers. However, no subject required any
treatment or hospitalization for this abnormality. Despite this,
pafuramidine is evidently a promising candidate for use as a
new drug for oral administration. It was therefore tested in the
vervet monkey model of sleeping sickness at the Trypanoso-
miasis Research Centre of the Kenya Agricultural Research
Institute. This nonhuman primate model is known to mimic the
human disease closely (21) and is a valuable tool for preclinical
chemotherapeutic studies. Experiments were conducted to de-
termine the efficacy of DB289 after multiple oral doses against
both early- and late-stage infections with T. brucei rhodesiense.
MATERIALS AND METHODS
Experimental animals. Fifteen vervet monkeys (Chrolocebus [Cercopithecus]
aethiops) of both sexes and weighing between 2.5 and 4.5 kg were obtained from
the Institute of Primate Research in Kenya. They were housed in quarantine for
a minimum of 90 days and screened for evidence of disease, including zoonotic
infections. They were also dewormed using albendazole (Valbazen; Utravetis
Ltd., Kenya) and treated for ectoparasites using carbaryl (1-naphthyl methylcar-
bamate) (Sevin; Bayer Ltd., Kenya). During that period, the monkeys became
accustomed to staying in individual squeeze-back stainless steel cages and to being
handled. They were fed twice daily on fresh vegetables and commercial monkey
cubes (Unga Ltd., Kenya) and given water ad libitum. Before the study, the
animals were transferred to experimental wards and acclimatized for a further 2
weeks.
Trypanosomes. The T. brucei rhodesiense stabilate used was KETRI 2537, a
derivative of EATRO 1989, isolated from a patient in Uganda by direct
inoculation of blood and lymph node aspirates into a monkey and later
cryopreserved (9).
Test drug. Pafuramidine (DB289) [2,5-bis(4-amidinophenyl)-furan-bis-O-
methlylamidoxime; MediChem, Lemont, IL] was provided by Immtech Pharma-
ceuticals, Inc., as a yellow powder.
Drug preparation. DB289 was prepared as a 1% suspension in distilled water
containing 0.5% (wt/vol) carboxymethylcellulose sodium and 0.1% (wt/vol)
Tween 80. The preparation was stored at 4°C and used for up to 3 days before
a fresh preparation was made.
Drug administration. The DB289 suspension was administered orally using a
gavage needle once daily for 5 or 10 days depending on the treatment regimen
for each group.
Experimental design. The 15 monkeys were randomized into five treatment
groups without sex bias (Tables 1 and 2).
The monkeys were all infected by intravenous injection of 104 trypanosomes
diluted from the infected blood of immunosuppressed donor mice using phos-
phate-buffered saline as previously described for the vervet monkey model (11,





wt (kg)  SE
% Wt change ata:
Mean preinfection
% PCV  SE
% Change in PCV ata:
Day
0 p.t.b Day 28 p.t.
c End
point Day 0 p.t.
b Day
28 p.t.c End point
1 (1) 3.15  0.45 2.20 2.1d 0 47.0  4.4 4.30 17.0d 23.40
2 (3) 3.18  0.33 5.00 6.60 1.60 46.0  4.4 9.40 2.90 3.60
3 (10) 2.88  0.43 6.30 0 3.50 40.3  2.5 5.80 1.60 13.20
4 (10) 4.25  0.52 4.20 5.20 0.70 51.7  6.1 25.80 13.50 7.70
5 (10) 3.32  0.60 10.50 8.10 2.10 47.7  1.5 41.30 9.10 1.40
a Percent change in body weight or PCV from preinfection values. A  indicates a decline.
b Values taken before the first treatment dose, i.e., on the 7th day p.i. for groups 1 to 3, 14th day p.i. for group 4, and 28th day p.i. for group 5.
c Data for groups 2 to 5 at 28 days p.t.
d Percent change in body weight and PCV at 1 day p.t. for group 1.
TABLE 2. Outcomes of treatment of T. brucei rhodesiense-infected







Time to detection of
trypanosomes in biological





MIT WS HCT MIT
HC 
CT
1 1 (5) 463 7 9 NC NC 0/3
484 NC 4 7 14
485 3 14 21
2 3 (5) 482 55 79 21 1/3
483 69 66 69 55
411 Cured
3 10 (5) 454 Cured 3/3
468 Cured
486 Cured
4 10 (5) 471 56 87 NC NC 1/3
478 Cured
488 ND 42 ND
5 10 (10) 490 ND 21 42 0/3
501 56 73 NC
520 ND 119 119
a ND, not detected for 180 days p.t.; WS, wet smear; HC, hemocytometer
counting; CT, concentration techniques for CSF; NC, trypanosome not cleared.
954 MDACHI ET AL. ANTIMICROB. AGENTS CHEMOTHER.
17). On the seventh day postinfection (p.i.) in an early-stage infection, animals in
groups 1, 2, and 3 were treated orally with pafuramidine at dose rates of 1, 3, and
10 mg/kg, respectively, for five consecutive days. The animals in the remaining
two groups, groups 4 and 5, were treated with 10 mg/kg for 10 consecutive days,
starting on the 14th day p.i. (group 4) or on the 28th day p.i. (group 5). The
monkeys were monitored for clinical changes and for the presence of trypano-
somes in body fluids. Once parasites were detected in any of the body fluids, the
monkeys were removed from the study through humane euthanasia.
Monitoring and sample collection. Physical examinations and sampling of
body fluids were carried out weekly for the first 28 days and then once every 2
weeks up to 100 days posttreatment and monthly thereafter until the end of the
experiment. Physical examinations and collection of blood and cerebrospinal
fluid (CSF) were undertaken on monkeys anesthetized with diazepam (May and
Baker, United Kingdom) at 1 mg/kg body weight and with ketamine hydrochlo-
ride (Rotexmedica, Trittau, Germany) at 15 mg/kg body weight. Posttreatment
monitoring was maintained for a period of 180 days.
At each time point, approximately 1 ml of blood was collected into EDTA by
inguinal venipuncture. In addition to blood samples, 1.5 ml of CSF was collected
by lumbar puncture of the anesthetized monkeys (11).
Blood collected by inguinal venipuncture was used for determinations of
the packed cell volume (PCV) using the microhematocrit method. White cells
in the CSF were counted using a hemocytometer chamber.
Determination of parasitemia. The determination of parasitemia started 3
days p.i. It was done by examination of wet films of ear prick blood according to
a method described previously by Herbert and Lumsden (13) (detection limit,
105 trypanosomes/ml of blood) or by the hematocrit centrifugation technique
(HCT) according to methods described previously by Woo (31) (detection limit,
103 trypanosomes/ml of blood). Blood collected by inguinal venipuncture was
used for parasitemia determinations using both the wet-film and HCT methods.
For estimation of parasites in the CSF, some of the free-flowing CSF was
collected into a capillary tube and immediately transferred into a hemocytometer
chamber to count the number of trypanosomes and white cells. Negative CSF
samples were then centrifuged and reexamined for trypanosomes. In cases where
no parasites were detected in either blood or CSF by the above-described
methods, Swiss white mice were used to test for the presence of trypanosomes
(11). Samples of 0.2 ml of blood or CSF were inoculated intraperitoneally into
two mice per sample.
RESULTS
Clinical disease before treatment. Following infection, try-
panosomes were detected in wet smears of peripheral blood
with a mean period of 4.2 days (range, 3 to 5 days). Enlarge-
ment of peripheral axillar and inguinal lymph nodes was ob-
served by the seventh day p.i., and enlargement of the spleen
was observed by the 14th day p.i. The monkeys became dull,
had rough hair coats, and showed a transient loss of appetite.
The rectal body temperature rose from a preinfection (0 days
p.i.) value of 38.2°C  0.2°C to 38.9°C  0.2°C (mean 
standard error). The rise in temperature was significant (P 
0.01) and coincided with peak parasitemia levels of 7 	 107
trypanosomes/ml of blood. Other clinical signs included loss of
body weight as the infection progressed. The decrease in mean
body weight was marginal (
6% of preinfection weight) for
animals treated while in the first stage of disease at 7 to 11 days
p.i. (groups 1 to 3), and a more substantial change (10.5%) was
found for animals (group 5) treated during late-stage disease at
28 days p.i. (Table 1). The changes in mean PCV were similarly
marginal for animals treated while in the early stage but more
pronounced for those treated while in the late stage of disease
(Table 1). Animals that were treated in the late stage of disease
also had confirmed trypanosomes in CSF (1 to 6 trypanosomes/
l) and elevated white cell counts (mean, 10 cells/l of CSF;
range, 4 to 20 cells/l of CSF).
Results of treatment with pafuramidine. Pafuramidine
treatment was shown to benefit most of the monkeys. Body
weights and PCV improved in all monkeys by the time of
termination of the experiment except for those in group 1
(Table 1). In some individuals, there was clearance of both
parasitemia and CSF parasitosis (Table 2). However, the onset
and durability of the beneficial effects of pafuramidine treat-
ment varied in the different groups.
Group 1 (1 mg/kg for 5 days per os). In group 1, trypano-
somes became undetectable in the blood by direct microscopy
or HCT a day after the last (fifth) drug dose and remained so
for a mean of 5 days (range, 3 to 9 days). However, even during
this period of apparent aparasitemia, viable trypanosomes
were isolated from the monkeys’ blood by the mouse inocula-
tion test (MIT), indicating that blood parasites were never
completely eliminated. In the CSF, trypanosomes were de-
tected first by MIT on 7 to 14 days posttreatment (p.t.) or 14 to
21 days p.t. by microscopy (direct hemocytometer counting or
concentration techniques), indicating that the drug treatment
delayed the onset of trypanosomes in the CSF. Clinical data,
especially the PCV, continued to decline (Table 1), indicating
that at the low dose of 1 mg/kg of body weight, pafuramidine
treatment did not cure any of the monkey infections. The
monkeys were humanely euthanized.
Group 2 (3 mg/kg for 5 days per os). Animals in group 2
became parasitologically negative by both blood and CSF on
the fifth day of dosing. However, two of the three monkeys
experienced recrudescence of trypanosomes, first in the CSF
and later in the blood (Table 2). In these two animals, CSF
trypanosomes were first detected by the MIT at 21 days p.t. and
then by direct microscopy (Table 2). In this group, treatment
led to improvement in both mean weight and mean PCV (Ta-
ble 1) although only one of three the monkeys fulfilled the
criteria of cure at 180 days p.t. The two monkeys that relapsed
were humanely euthanized.
Group 3 (10 mg/kg for 5 days per os). Animals in group 3
became parasitologically negative by the fifth day of dosing and
remained so until the end of the experimental period. Simi-
larly, no trypanosomes were recovered by MIT throughout the
180 days of p.t. monitoring. Meanwhile, weight and PCV re-
turned to preinfection levels by 28 days p.t. (Table 1), and all
clinical aberrations resolved, underlining that all three of three
monkeys were cured of the infection.
Group 4 (10 mg/kg for 10 days per os starting 14 days p.i.).
In group 4, following treatment, both weight and PCV im-
proved, although not to preinfection levels (Table 1). All three
monkeys in this group became aparasitemic by day 5 of dosing,
but only two of three monkeys (monkeys 478 and 488) re-
mained free of blood parasites until 180 days p.t. In the CSF,
either trypanosomes were not cleared (monkey 471) or recru-
descence occurred within the first 42 days p.t. (monkey 488)
(Table 2). Only monkey 478 remained free of trypanosomes in
both blood and CSF as determined by HCT and MIT and was
considered to be cured (Table 2). The results were confirmed
by the pattern of white cell changes in the CSF; these oscillated
between 0 and 12 cells/l of CSF for monkey 478, which was
cured, but occasional peaks of above 25 cells/l of CSF, which
declined to lower peaks below 15 cells/l of CSF, were ob-
served in monkey 488, where there was recrudescence of the
infection (Fig. 1).
Group 5 (10 mg/kg for 10 days per os starting at 28 days
p.i.). In group 5, all the animals became aparasitemic by day 4
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of dosing. However, only two of three of them remained free of
blood trypanosomes by the end of the 180 days of p.t. moni-
toring (Table 2). In the CSF, trypanosomes were not cleared in
monkey 501, while in the remaining two monkeys, the trypano-
somes disappeared after treatment, and recrudescence oc-
curred (Table 2). The significant improvement in weight and
PCV (Table 1) was probably due to the absence of trypano-
somes from the hemolymphatic system in spite of the presence
of trypanosomes in the CNS.
DISCUSSION
In this study, the oral administration of pafuramidine
(DB289) had a profound effect on established T. brucei rhod-
esiense infections in vervet monkeys. In the acute disease stage,
when the monkeys showed high parasitemia levels, treatment
with 10 mg/kg orally for five consecutive days cleared three of
the three monkeys in group 3 of their trypanosome infections
and kept them trypanosome free for the entire monitoring
period of 180 days. In addition, the treatment reversed the
clinical symptoms of trypanosomiasis, thus fulfilling all criteria
for confirmation of cure.
Comparison of this group of monkeys with groups 1 and 2,
which also had an early-stage infection with a 5-day treatment
schedule (days 7 to 11), shows a clear dose response to pafura-
midine. At 3 mg/kg, only one of three animals was cured, and
at the lowest dose, 1 mg/kg, all animals relapsed within 1 week
after treatment or did not clear parasitemia at all.
The clinical signs described in this report for acute infection
mirror those described in previous reports for syringe passage
of T. brucei rhodesiense infections in vervet monkeys (15, 21),
tsetse-transmitted infections in vervet monkeys (28), and early-
stage infections in sleeping sickness patients (16, 18, 22). These
clinical manifestations are evidence of hemolymphatic system
involvement. The fact that the clinical manifestations were
reversed when pafuramidine was administered in sufficient
concentrations indicates that the drug was able to access and
eliminate trypanosomes from all hemolymphatic sites.
In the two groups of monkeys with a late-stage infection,
treatment with 10 mg/kg for 10 days cured only one of three
monkeys treated from 14 days p.i. (group 4) and none in the
group treated from 28 days p.i. onwards. In group 4, the pres-
ence of trypanosomes and white cell counts above the 5-cell/
mm3 cutoff for confirmation of late-stage disease (29) was
demonstrated in the CSF of the infected monkeys. The fact
that trypanosomes were eliminated from the CSF in one ani-
mal and the mean PCV in the group was improved (from
25.8% to 13.5%) (Table 1) suggests that orally adminis-
tered pafuramidine has some ability to cross the blood-brain
barrier. Although the levels of pafuramidine (DB289) and its
active form, furamidine (DB75), in CSF were not determined
in the present study, it is likely that the variation in individual
responses resulted from variation in the CSF levels of the
drugs. Generally, the activity of a drug may show considerable
interanimal variation, which results in different concentrations
at the site of action (kinetic differences) or different responses
to a given drug concentration (dynamic differences) (19). Stud-
ies with melarsoprol, the drug used to treat late-stage sleeping
sickness, similarly indicated that the peak levels attained in the
CSF of monkeys were about 50 times less than peak levels in
plasma and were insufficient in some animals to eliminate all
trypanosomes from the CSF compartment (6).
The fact that none of the animals treated with pafuramidine
at 10 mg/kg for 10 days starting at 28 days p.i. was cured shows
that as the residence time of trypanosomes in the CSF in-
creased, the infections became more difficult to treat. It has
been postulated that the invasion of the CSF by trypanosomes
progressively leads to parasite invasion of the perivascular
FIG. 1. CSF white cell changes in vervet monkeys 478 (Œ) and 488 () after treatment with pafuramidine at 10 mg/kg for 10 days while in the
late stage (14 days p.i.) of disease. Note that in vervet monkey 478, levels of white cells declined after treatment and remained low throughout the
observation period, while in vervet monkey 488, the drop in white cell number was transient and showed recrudescences to 25 cells/l of CSF.
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spaces (Virchow-Robin spaces) and from there to the paren-
chyma of the CNS (20). Further evidence of the importance of
the residence time of trypanosomes in CSF was provided pre-
viously by Schmidt and Sayer (21), who found that one monkey
with a disease duration of 107 days had histologically demon-
strable meningoencephalitis. Although our study had no com-
ponent of histology and could therefore not confirm or rule out
the presence of meningoencephalitis at 28 days p.i., it is clear
that the levels of the active drug (DB75) attained in the CSF
were inadequate to eliminate trypanosomes from the sites to
which they were sequestered, making the CNS the main source
of relapse parasites, as previously observed for mice (14). Even
in this group of monkeys, however, the drug cleared blood-
stream-form trypanosomes and maintained two of three mon-
keys trypanosome free throughout the monitoring period,
which provides further evidence of the ability of pafuramidine
to access hemolymphatic but not CNS sites of the infected
monkeys.
To conclude, the study showed that the novel prodrug
pafuramidine (DB289) was effective against early T. brucei rhod-
esiense infection in monkeys. In addition, the drug was well
tolerated by all the infected monkeys, confirming previous
observations of uninfected vervet monkeys (John Thuita,
TRC-KARI, personal communication). The drug was gener-
ally not effective against late-stage disease and may therefore
not be indicated for this use. However, Sturk et al. (24) previ-
ously observed that after intravenous administration in mice,
there was a fivefold increase in brain levels of pafuramidine
with parenchymal localization of compound fluorescence,
which suggested that the unaltered prodrug does penetrate
the blood-brain barrier and may be subject to in situ bio-
transformation. Since the present study showed that pafura-
midine was efficacious in clearing trypanosomes from the
bloodstream, it would be worth considering the testing of
parenteral treatment regimens to improve the bioavailabil-
ity of the drug in the CNS in nonhuman primates. However,
the issue of recently found human toxicity should be taken in
consideration in further nonhuman primate studies.
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